EKSO - Ekso Bionics Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.4900
-0.0400 (-2.61%)
At close: 4:00PM EDT

1.4800 -0.01 (-0.67%)
After hours: 4:36PM EDT

Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close1.5300
Open1.5100
Bid1.4900 x 2200
Ask1.6000 x 800
Day's Range1.4600 - 1.5200
52 Week Range1.1800 - 3.3000
Volume403,180
Avg. Volume415,984
Market Cap100.827M
Beta (3Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire4 hours ago

    Ekso Bionics Announces Closing of $10 Million Public Offering

    Ekso Bionics Holdings, Inc. (EKSO) (the “Company,” “Ekso” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, announced today the closing of its previously announced underwritten public offering of 6,666,667 shares of its common stock and accompanying warrants to purchase 6,666,667 shares of its common stock, at a price to the public of $1.50 per share and accompanying warrant to purchase one share of common stock, for gross proceeds of $10.0 million before deducting underwriters’ discounts, commissions and estimated offering expenses. The securities described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-218517) relating to the public offering of such securities, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 6, 2017 and declared effective by the SEC on June 16, 2017.

  • GlobeNewswire2 days ago

    Ekso Bionics Announces Pricing of $10 Million Public Offering

    Ekso Bionics Holdings, Inc. (EKSO) (the “Company,” “Ekso” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, announced today the pricing of its previously announced underwritten public offering of 6,666,667 shares of its common stock and accompanying warrants to purchase 6,666,667 shares of its common stock, at a price to the public of $1.50 per share and accompanying warrant to purchase one share of common stock, for expected gross proceeds of $10.0 million before deducting underwriters’ discounts, commissions and estimated offering expenses. Cantor Fitzgerald & Co. is acting as lead book-running manager and SunTrust Robinson Humphrey, Inc. is acting as joint book-running manager for the offering.

  • GlobeNewswire3 days ago

    Ekso Bionics Announces Proposed Public Offering of Common Stock and Warrants

    Ekso Bionics Holdings, Inc. (EKSO) (the “Company,” “Ekso” or “Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it is commencing an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. All the shares and warrants to be sold in the offering will be offered by Ekso. The Company intends to use the net proceeds, if any, from the sale of the shares of common stock and warrants in the offering (and from the exercise, if any, of the warrants issued in the offering) for general corporate purposes, which may include acquisitions, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs.

  • GlobeNewswire18 days ago

    Ekso Bionics®’ EksoGT Exoskeleton Adopted in Singapore for Groundbreaking Clinical Study

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that the National University Health System (NUHS) in Singapore has adopted three EksoGT exoskeletons for a groundbreaking clinical study. NUHS is one of the first national health systems in Asia to study how advanced exoskeleton technology can improve mobility and rehabilitation outcomes, and the first to study it across the entire continuum of care. The Improving Mobility via Exoskeletons (iMOVE) program, supported by Temasek Foundation and Trailblazer Foundation Limited, will study patient outcomes and assess the viability and potential for scaling-up the use of robotic exoskeletons across the continuum of rehabilitation care from hospital to community.  The study will focus on patients suffering from stroke and spinal cord injuries, especially for the elderly.  The three EksoGT devices will be used at multiple NUHS partner sites including Alexandra Hospital, NTUC Health, St Luke’s Eldercare, St Luke’s Hospital, and Stroke Support Station.

  • GlobeNewswire18 days ago

    Ekso Bionics Announces Appointment of Bill Shaw as Chief Commercial Officer

    Ekso Bionics Holdings, Inc. (EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Bill Shaw as Chief Commercial Officer, with a start date of May 6, 2019.  Mr. Shaw will be responsible for overseeing Ekso Bionics’ global commercialization strategy and will focus on accelerating adoption of the Company’s medical technologies. Mr. Shaw brings more than 15 years of medical device sales and leadership experience to Ekso Bionics.  Most recently, Mr. Shaw served as Global Vice President of Robotic Surgery at Zimmer Biomet.

  • GlobeNewswire21 days ago

    Kindred Hospital Rehabilitation Services Expands Pilot of Ekso Bionics®’ EksoGT Exoskeleton to Enhance Stroke Rehabilitation Offering

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that Kindred Hospital Rehabilitation Services ("Kindred"), a division of Kindred Healthcare, has expanded their pilot of the EksoGT exoskeleton to offer advanced stroke rehabilitation at the majority of their sites - over 20 freestanding inpatient Kindred rehabilitation hospitals in 13 states. The pilot began over a year ago and has since been expanded to the majority of their sites, making Kindred Ekso Bionics’ largest partner offering EksoGT at the most locations within a single network. “It is our mission to provide greater access to advanced rehabilitation, and we are excited to incorporate the EksoGT into our offering at most of our inpatient rehabilitation hospitals,” said Russ Bailey, COO/Senior Vice President of Operations at Kindred.

  • GlobeNewswire23 days ago

    Ekso Bionics Reports First Quarter 2019 Results

    RICHMOND, Calif., May 01, 2019 -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today.

  • GlobeNewswirelast month

    Ekso Bionics® to Report First Quarter 2019 Financial Results on May 1, 2019

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter 2019 after the close of trading on Wednesday, May 1, 2019. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.

  • GlobeNewswire3 months ago

    Ekso Bionics Reports Fourth Quarter and Year End 2018 Results

    RICHMOND, Calif., Feb. 28, 2019 -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today reported.

  • GlobeNewswire3 months ago

    Ekso Bionics® to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2018 after the close of trading on Thursday, February 28, 2019. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.

  • ACCESSWIRE4 months ago

    4 Healthcare Stocks Looking To Finish Strong On Wednesday (1/30/19)

    Premier Health Group (PHGRF) (PHGI), China SXT Pharmaceuticals Inc (SXTC), eHealth Inc (EHTH), and Ekso Bionics Holdings Inc (EKSO) represent four healthcare companies determined to provide the best quality of care for consumers in need. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments meant to demonstrate to both investors and consumers that the Company is determined to invest in the future of its customers. Premier Health Group (PHGRF) (PHGI) announced earlier this week that, further to its new release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • GlobeNewswire4 months ago

    Ekso Bionics Announces $100 Million Joint Venture to Develop the Exoskeleton Market in Asia

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that its wholly-owned subsidiary, Ekso Bionics, Inc., has entered into an agreement with Zhejiang Youchuang Venture Capital Investment Co., Ltd (ZYVC) and another partner to establish a joint venture designed to develop and serve the exoskeleton market in China and other Asian markets and to create a global exoskeleton manufacturing center. Stroke is the leading cause of death in China, and about 2 million Chinese die of stroke-related illnesses every year.  There are currently 12 million stroke patients in the country and the number is expected to more than double to 30 million by 2030.

  • GlobeNewswire4 months ago

    Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2018. Total revenue for the fourth quarter of 2018 is an estimated $3.3 million reflecting year-over-year growth of 32% compared to total revenue of $2.5 million in the fourth quarter of 2017. Total revenue for the fourth quarter of 2018 includes approximately $2.4 million in medical revenue.

  • GlobeNewswire5 months ago

    Ekso Bionics® Secures Purchase Orders for the EksoVest™ from Two Global Aerospace Manufacturers

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has secured purchase orders for the EksoVest™ from two global aerospace manufacturers to create and expand pilot programs, respectively. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market.

  • GlobeNewswire6 months ago

    Worldwide Adoption of Ekso Bionics® EksoGT™ Exoskeleton Allows Stroke and Spinal Cord Injury Patients to Take 100 Million Steps to Date

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industry use, today announced that the worldwide adoption of the EksoGT™ exoskeleton has allowed stroke and spinal cord injury patients to take 100 million steps to date (click to tweet). More than 240 leading rehabilitation centers in over 30 countries helped their patients walk 50,000 miles in the EksoGT exoskeleton— the distance of walking around the world twice. Centers utilizing the EksoGT are advancing both in-patient and outpatient rehabilitation, and collectively changing the standard of care to promote better patient outcomes.

  • GlobeNewswire7 months ago

    Ekso Bionics Reports Third Quarter 2018 Results

    RICHMOND, Calif., Nov. 07, 2018 -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today reported.

  • GlobeNewswire7 months ago

    Ekso Bionics Appoints Thomas Schreck to its Board of Directors

    Ekso Bionics Holdings, Inc. (NASDAQ:  EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Thomas Schreck to its Board of Directors, effective immediately. “We are pleased to welcome Thomas to our Board,” said Steven Sherman, Chairman of the Board of Ekso Bionics. “With past successes in leading several pharmaceutical and medical device companies, Thomas brings a wealth of experience commercializing innovative solutions that align with our corporate strategy.

  • GlobeNewswire7 months ago

    Ekso Bionics® to Report Third Quarter 2018 Financial Results on November 7, 2018

    Ekso Bionics Holdings, Inc. (EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the third quarter 2018 after the close of trading on Wednesday, November 7, 2018.  Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. Investors interested in listening to the conference call may do so by dialing (877) 407-3036 for domestic callers or (201) 378-4919 for international callers.  A live webcast of the event will be available in the “Investors” section of the company’s website at www.eksobionics.com, or by clicking here. A replay of the call will be available for two weeks by dialing (877) 660-6853 for domestic callers or (201) 612-7415 for international callers and using Conference ID: 13581989.  The webcast will also be available on the company’s website for one month following the completion of the call.

  • ACCESSWIRE9 months ago

    With Overhang Gone, BTCY Could Generate Triple Digit Returns for Shareholders

    Investors recently long EKSO have made 65% with more potential upside to come. Tandem Diabetes Care, Inc. (TNDM) has traded from $2 to $34/share this year, a gain of over 1700%. This is based on improving commercial success with their diabetes business and another FDA approval in the summer.

  • ACCESSWIRE9 months ago

    Today’s Research Reports on Stocks to Watch: Spark Therapeutics and Ekso Bionics

    Shares of Ekso Bionics saw big gains during the trading day but lost almost 11% in after-hours trading. The company reported second quarter results that didn’t hit estimates. Spark Therapeutics, Inc. shares closed down 27.83% on Tuesday, on significant trading volume compared to usual.